Press Releases Mar 13, 2023 Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic Feb 28, 2023 Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress Jan 10, 2023 Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC View all press releases Presentations & Events View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
Mar 13, 2023 Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
Feb 28, 2023 Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
Jan 10, 2023 Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC